Investor Relations

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, Maveropepimut-S (DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing Maveropepimut-S as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.

View Management Team View Board of Directors

Investor Relations

Upcoming Event

Society for Immunotherapy of Cancer (SITC) Annual Meeting

Latest News

Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Latest Presentation

Corporate Presentation

Latest Financial Results

Q2 2021

Latest Annual Filing

Stock Snapshot

Company Overview

Investor Contact Information

Headquarters

Corporate Office